Published November 17, 2021
Tyrosine kinase inhibitors (TKIs) are a class of drugs often used to treat a variety of different cancers, usually with significant success.
Unfortunately, when these drugs are used in combination with other medications, harmful side effects can be experienced by patients.
Jason Sprowl, PhD, is the recipient of a multi-year, $2.3 million grant from the National Institutes of Health to explore how TKIs inactivate specific drug transporting proteins in the liver that under normal circumstances regulate clearance of drugs. Without these proteins being active, the levels of co-administered medications in the blood will rise which can lead to potentially life-threatening side effects.
“To date our group has already discovered that tyrosine kinase inhibitors turn off proteins that keep these transporter proteins in an active state” Sprowl says. “This study will investigate how this inactivation occurs and will help in the design of new therapeutics or dosing strategies that will sustain the function of these important proteins, thus preventing life threatening side effects.”
The grant runs through August 2026.